Quest for the right Drug
נוברינג NUVARING (ETHINYLESTRADIOL, ETONOGESTREL)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
וגינלי : VAGINAL
צורת מינון:
טבעת וגינלית : VAGINAL RING
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects The most frequently reported undesirable effects in the clinical trials with NuvaRing were headache and vaginal infections and vaginal discharge, each reported by 5-6% of the women. Description of selected adverse reactions An increased risk of arterial and venous thrombotic and thromboembolic events, including myocardial infarction, stroke, transient ischaemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs, which are discussed in more detail in section 4.4. Also other undesirable effects have been reported in women using CHCs: these are discussed in more detail in section 4.4. Adverse drug reactions that have been reported in clinical trials, observational studies, or during postmarketing use with NuvaRing are listed in the Table below. The most appropriate MedDRA term to describe a certain adverse event is listed. All adverse reactions are listed by system organ class and frequency; common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), and not known (cannot be estimated from the available data). System Organ Common Uncommon Rare Not known1 Class Infections and Vaginal infection Cervicitis, infestations Cystitis, Urinary tract infection Immune system Hypersensitivity disorders reactions, including anaphylaxis and exacerbation of symptoms of hereditary and acquired angioedema Metabolism and Increased nutrition appetite disorders Psychiatric Depression, Affect lability, disorders Libido Mood altered, decreased Mood swings Nervous system Headache, Dizziness, disorders Migraine Hypoaesthesia Eye disorders Visual disturbance Vascular Hot flush Venous disorders thromboembolism Arterial thromboembolism Gastrointestinal Abdominal pain, Abdominal disorders Nausea distension, Diarrhoea, Vomiting, Constipation Skin and Acne Alopecia, Chloasma subcutaneous Eczema, tissue disorders Pruritus, Rash Urticaria Musculoskeletal Back pain, and connective Muscle spasms, tissue disorders Pain in extremity Renal and Dysuria, urinary disorders Micturition urgency, Pollakiuria Reproductive Breast Amenorrhoea, Galactorrhoea Penis disorders system and tenderness, Breast breast disorders Genital pruritus discomfort, female, Breast Dysmenorrhoea, enlargement, Pelvic pain, Breast mass, Vaginal Cervical polyp, discharge Coital bleeding, Dyspareunia, Ectropion of cervix, Fibrocystic breast disease, Menorrhagia, Metrorrhagia, Pelvic discomfort, Premenstrual syndrome, Uterine spasm, Vaginal burning sensation, Vaginal odour, Vaginal pain, Vulvovaginal discomfort, Vulvovaginal dryness General Fatigue, Vaginal ring site disorders and Irritability, tissue administration Malaise, overgrowth site conditions Oedema, Sensation of foreign body Investigations Weight Blood pressure increased increased Injury, poisoning Vaginal ring Vaginal ring Vaginal injury and procedural discomfort, complication associated with complications Vaginal ring ring expelled breakage Listing of adverse events based on spontaneous reporting. Hormone-dependent tumours (e.g. liver tumours, breast cancer) have been reported in association with CHC use. For further information see section 4.4. On very rare occasions NuvaRing has been reported to get disconnected during use (see sections 4.4 and 4.5). Interactions Breakthrough bleeding and/or contraceptive failure may result from interactions of other drugs (enzyme inducers) with hormonal contraceptives (see section 4.5). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף
עלון מידע לצרכן
16.03.22 - עלון לצרכן אנגלית 16.03.22 - עלון לצרכן עברית 18.04.22 - עלון לצרכן ערבית 18.10.22 - עלון לצרכן עברית 06.12.22 - עלון לצרכן אנגלית 06.12.22 - עלון לצרכן ערבית 03.10.24 - עלון לצרכן אנגלית 03.10.24 - עלון לצרכן עברית 03.10.24 - עלון לצרכן ערבית 10.10.24 - עלון לצרכן עברית 27.05.15 - החמרה לעלון 23.01.17 - החמרה לעלון 16.03.22 - החמרה לעלון 18.10.22 - החמרה לעלוןלתרופה במאגר משרד הבריאות
נוברינג